Kazia Therapeutics (NASDAQ:KZIA) Rating Increased to Buy at ValuEngine
Separately, Zacks Investment Research downgraded shares of Kazia Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd.
Shares of KZIA stock opened at $2.43 on Tuesday. The company’s fifty day simple moving average is $2.58 and its 200-day simple moving average is $3.07. Kazia Therapeutics has a 52 week low of $2.04 and a 52 week high of $4.27. The company has a market cap of $14.80 million, a PE ratio of -2.51 and a beta of 1.52.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.
Recommended Story: How Investors Can Profit from Options Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.